Trial Profile
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower030
- Sponsors Roche
- 06 Apr 2023 Planned End Date changed from 20 Nov 2024 to 19 Jan 2025.
- 06 Apr 2023 Planned primary completion date changed from 20 Nov 2024 to 19 Jan 2025.
- 25 Mar 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.